eslicarbazepine acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4303 236395-14-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eslicarbazepine acetate
  • zebinix
  • exelief
  • aptiom
  • BIA 2-093
  • Sep-0002093
Eslicarbazepine acetate is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
  • Molecular weight: 296.33
  • Formula: C17H16N2O3
  • CLOGP: 1.50
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.63
  • ALOGS: -3.43
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

PropertyValueReference
S (Water solubility) 4.20 mg/mL Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.39 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 95 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PRKDC,STK33,TEK,TTK 20
kinase-selectivity-class ACVR2B,AXL,BRAF,GRK2,MAP2K6,PDK4,STK33 7
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Nov. 8, 2013 FDA SUNOVION PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 270.21 42.73 99 1396 152530 90474422
Hyponatraemia 168.90 42.73 68 1427 133470 90493482
Generalised tonic-clonic seizure 81.59 42.73 28 1467 34875 90592077
Axillary lymphadenectomy 50.04 42.73 7 1488 116 90626836
Drug dose titration not performed 43.58 42.73 8 1487 764 90626188

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 271.27 43.11 103 936 120458 42499838
Drug ineffective 61.05 43.11 75 964 630122 41990174
Hyponatraemia 58.06 43.11 34 1005 101428 42518868
Status epilepticus 51.99 43.11 18 1021 15560 42604736
Multiple-drug resistance 47.34 43.11 14 1025 7308 42612988

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 350.45 37.75 138 1993 221047 110366121
Hyponatraemia 179.57 37.75 86 2045 217567 110369601
Generalised tonic-clonic seizure 68.37 37.75 29 2102 54651 110532517
Multiple-drug resistance 63.24 37.75 19 2112 13216 110573952
Status epilepticus 57.65 37.75 22 2109 31549 110555619
Petit mal epilepsy 54.74 37.75 15 2116 7532 110579636
Drug ineffective 54.53 37.75 101 2030 1520439 109066729
Axillary lymphadenectomy 50.47 37.75 7 2124 92 110587076
Somnolence 49.71 37.75 43 2088 297406 110289762
Inappropriate antidiuretic hormone secretion 45.79 37.75 19 2112 33832 110553336
Psychomotor skills impaired 41.93 37.75 12 2119 7046 110580122

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AF04 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Carboxamide derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA D000927 Anticonvulsants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

N03AF Carboxamide derivatives 3 drugs
carbamazepineoxcarbazepinerufinamide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Partial seizure indication 29753000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.73 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9763954 Sept. 13, 2028 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
400MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9763954 Sept. 13, 2028 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
600MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9763954 Sept. 13, 2028 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
800MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9763954 Sept. 13, 2028 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
200MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES
200MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
400MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES
400MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
600MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES
600MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
800MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES
800MG APTIOM SUMITOMO PHARMA AM N022416 Nov. 8, 2013 RX TABLET ORAL 9750747 Aug. 24, 2032 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel alpha subunit Ion channel BLOCKER CHEMBL CHEMBL

External reference:

IDSource
4033118 VUID
N0000190128 NUI
D09215 KEGG_DRUG
4033116 VANDF
4033118 VANDF
C2725262 UMLSCUI
CHEMBL87992 ChEMBL_ID
DB09119 DRUGBANK_ID
C416835 MESH_SUPPLEMENTAL_RECORD_UI
BEA68ZVB2K UNII
179344 PUBCHEM_CID
DB14575 DRUGBANK_ID
1482501 RXNORM
207443 MMSL
29871 MMSL
394837 MMSL
d07507 MMSL
013276 NDDF
013277 NDDF
697998007 SNOMEDCT_US
700015007 SNOMEDCT_US
715615002 SNOMEDCT_US
C2725260 UMLSCUI
CHEMBL315985 ChEMBL_ID
104746-04-5 SECONDARY_CAS_RN
9881504 PUBCHEM_CID
7350 IUPHAR_LIGAND_ID
8403 INN_ID
C571001 MESH_SUPPLEMENTAL_RECORD_UI
S5VXA428R4 UNII
CHEBI:174358 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 13668-538 TABLET 200 mg ORAL ANDA 30 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 13668-539 TABLET 400 mg ORAL ANDA 30 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 13668-540 TABLET 600 mg ORAL ANDA 30 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 13668-541 TABLET 800 mg ORAL ANDA 30 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 31722-428 TABLET 200 mg ORAL ANDA 31 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 31722-429 TABLET 400 mg ORAL ANDA 31 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 31722-430 TABLET 600 mg ORAL ANDA 31 sections
Eslicarbazepine acetate HUMAN PRESCRIPTION DRUG LABEL 1 31722-431 TABLET 800 mg ORAL ANDA 31 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-684 TABLET 200 mg ORAL ANDA 30 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-685 TABLET 400 mg ORAL ANDA 30 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-686 TABLET 600 mg ORAL ANDA 30 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-687 TABLET 800 mg ORAL ANDA 30 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51407-779 TABLET 200 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51407-780 TABLET 400 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51407-781 TABLET 600 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51407-782 TABLET 800 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate Human Prescription Drug Label 1 59746-717 TABLET 200 mg ORAL ANDA 21 sections
Eslicarbazepine Acetate Human Prescription Drug Label 1 59746-718 TABLET 400 mg ORAL ANDA 21 sections
Eslicarbazepine Acetate Human Prescription Drug Label 1 59746-719 TABLET 600 mg ORAL ANDA 21 sections
Eslicarbazepine Acetate Human Prescription Drug Label 1 59746-720 TABLET 800 mg ORAL ANDA 21 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4658 TABLET 200 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4659 TABLET 400 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4660 TABLET 600 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4661 TABLET 800 mg ORAL ANDA 32 sections
Aptiom HUMAN PRESCRIPTION DRUG LABEL 1 63402-202 TABLET 200 mg ORAL NDA 32 sections
Aptiom HUMAN PRESCRIPTION DRUG LABEL 1 63402-204 TABLET 400 mg ORAL NDA 32 sections
Aptiom HUMAN PRESCRIPTION DRUG LABEL 1 63402-206 TABLET 600 mg ORAL NDA 32 sections
Aptiom HUMAN PRESCRIPTION DRUG LABEL 1 63402-208 TABLET 800 mg ORAL NDA 32 sections
Eslicarbazepine Acetate Human Prescription Drug Label 1 67877-585 TABLET 200 mg ORAL ANDA 32 sections
Eslicarbazepine Acetate Human Prescription Drug Label 1 67877-586 TABLET 400 mg ORAL ANDA 32 sections